Fig. 3From: NCAPD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancerSurvival analysis of NCAPD2 in pan-cancer. (A) The OS of patients with NCAPD2. (B) The DFS of patients with NCAPD2. (C) The survival of patients with NCAPD2 in breast, ovarian, gastric, lung and liver cancer (all P < 0.05)Back to article page